Curi RMB Capital LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 87,698 shares of the company's stock, valued at approximately $6,446,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Banque Transatlantique SA increased its stake in shares of AstraZeneca by 35,291.5% during the 1st quarter. Banque Transatlantique SA now owns 142,274 shares of the company's stock worth $9,664,000 after purchasing an additional 141,872 shares during the last quarter. AQR Capital Management LLC grew its holdings in AstraZeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company's stock valued at $2,756,000 after purchasing an additional 11,690 shares during the period. Aprio Wealth Management LLC grew its holdings in AstraZeneca by 116.7% during the first quarter. Aprio Wealth Management LLC now owns 10,452 shares of the company's stock valued at $768,000 after purchasing an additional 5,629 shares during the period. Adage Capital Partners GP L.L.C. increased its position in AstraZeneca by 83.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 647,271 shares of the company's stock worth $47,574,000 after buying an additional 293,833 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its stake in shares of AstraZeneca by 7.2% in the first quarter. Federation des caisses Desjardins du Quebec now owns 230,607 shares of the company's stock valued at $16,950,000 after buying an additional 15,554 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Price Performance
AstraZeneca stock opened at $81.78 on Friday. The stock has a market cap of $253.63 billion, a price-to-earnings ratio of 30.74, a PEG ratio of 1.51 and a beta of 0.37. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The business has a 50-day simple moving average of $74.66 and a 200 day simple moving average of $72.70. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $84.30.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter last year, the company posted $1.24 EPS. The company's revenue for the quarter was up 16.1% on a year-over-year basis. On average, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
AstraZeneca Cuts Dividend
The business also recently declared a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be paid a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date of this dividend is Friday, August 8th. AstraZeneca's payout ratio is currently 37.97%.
Analysts Set New Price Targets
Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $86.00.
Check Out Our Latest Research Report on AstraZeneca
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
